Mundelein, IL, United States of America

Michael D Serby


Average Co-Inventor Count = 6.9

ph-index = 2

Forward Citations = 38(Granted Patents)


Company Filing History:


Years Active: 2007-2011

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Michael D Serby: Innovator in Pharmaceutical Compounds

Introduction

Michael D Serby is a notable inventor based in Mundelein, IL (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific biological pathways. With a total of two patents to his name, Serby's work has the potential to impact the treatment of various disorders.

Latest Patents

Serby's latest patents include innovative compounds that serve as inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3). These compounds are designed to be used in the prevention or treatment of disorders regulated by the activation of these kinases. Another patent focuses on protein-tyrosine phosphatase inhibitors, specifically targeting protein tyrosine phosphatase-1B (PTP1B). This invention aims to provide therapeutic options for disorders caused by the overexpression or alteration of PTP1B.

Career Highlights

Michael D Serby is associated with Abbott Laboratories Corporation, a leading company in the healthcare sector. His work at Abbott has allowed him to contribute to groundbreaking research and development in pharmaceuticals.

Collaborations

Throughout his career, Serby has collaborated with esteemed colleagues, including Zhili Xin and Gang Liu. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Michael D Serby is a distinguished inventor whose work in pharmaceutical compounds demonstrates his commitment to advancing medical science. His patents reflect a deep understanding of complex biological mechanisms and a dedication to improving patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…